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Abstract
Background: A common element among cancer cells is the presence of improperly controlled
transcription. In these cells, the degree of specific activation of some genes is abnormal, and altering
the aberrant transcription may therefore directly target cancer. TFIIS is a transcription elongation
factor, which directly binds the transcription motor, RNA Polymerase II and allows it to read
through various transcription arrest sites. We report on RNA interference of TFIIS, a transcription
elongation factor, and its affect on proliferation of cancer cells in culture.
Methods: RNA interference was performed by transfecting siRNA to specifically knock down
TFIIS expression in MCF7, MCF10A, PL45 and A549 cells. Levels of TFIIS expression were
determined by the Quantigene method, and relative protein levels of TFIIS, c-myc and p53 were
determined by C-ELISA. Induction of apoptosis was determined by an enzymatic Caspase 3/7 assay,
as well as a non-enzymatic assay detecting cytoplasmic mono- and oligonucleosomes. A gene array
analysis was conducted for effects of TFIIS siRNA on MCF7 and MCF10A cell lines.
Results: Knockdown of TFIIS reduced cancer cell proliferation in breast, lung and pancreatic
cancer cell lines. More specifically, TFIIS knockdown in the MCF7 breast cancer cell line induced
cancer cell death and increased c-myc and p53 expression whereas TFIIS knockdown in the non-
cancerous breast cell line MCF10A was less affected. Differential effects of TFIIS knockdown in
MCF7 and MCF10A cells included the estrogenic, c-myc and p53 pathways, as observed by C-ELISA
and gene array, and were likely involved in MCF7 cell-death.
Conclusion: Although transcription is a fundamental process, targeting select core transcription
factors may provide for a new and potent avenue for cancer therapeutics. In the present study,
knockdown of TFIIS inhibited cancer cell proliferation, suggesting that TFIIS could be studied as a
potential cancer target within the transcription machinery.
Background
An underlying mechanism of breast and other cancers
involves aberrant transcription with numerous genes up
or down-regulated [1-6]. It is reasonable to assume that
further perturbing the improper transcription occurring in
cancer cells could result in cancer cell death. Transcrip-
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tion, however, is a fundamental cellular process, and its
targeting may affect non-cancerous cells. Nonetheless, it
has been proposed that targeting transcription is possible
and challenges in attaining cancer specificity can be over-
come [7].
RNA Polymerase II (RNAP) is the multisubunit enzyme
responsible for generating all mRNA in eukaryotic cells
[8,9]. All stages of regulation of RNAP could be potential
targets for cancer therapy including initiation and/or ter-
mination of the transcription process as well as elonga-
tion of the mRNA and termination. Another target could
include components of the machinery involved in chro-
matin remodeling and the positioning of nucleosomes,
structures composed of DNA wrapped around a histone
protein core [10,11]. Chromatin remodeling is important
in allowing RNAP access to DNA such that histone
deacetylase (HDAC) inhibitors, which modulate nucleo-
some structure, are effective as anticancer agents [12,13].
We tested knockdown of several components of the tran-
scription machinery for effects on cancer cells and found
TFIIS knockdown of interest for further analysis. During
transcript elongation, RNAP can arrest on specific DNA
sequences including Poly T stretches, unable to complete
the synthesis of mRNA [14,15]. When RNAP arrests, the
active site disengages from the 3' end of the transcript and
repositions itself over an internal phosphodiester bond
and is therefore incapable of adding ribonucleotide sub-
strates [16]. TFIIS reactivates arrested transcription by
stimulating RNAP endonucleolytic cleavage of the tran-
script [17,18]. Once cleavage of the RNA is completed, the
active site is correctly positioned at the new 3'-end of the
RNA chain allowing for chain extension. As a result, TFIIS
induced readthrough of arrest sites produces both a 7–9
base RNA cleavage product and a full-length readthrough
product.
However, alternate mechanisms exist to deal with arrested
transcription. Transcription elongation factors such as
TFIIF, ELL and Elongin are able to suppress arresting so
that there is no need for reactivation [19]. Alternatively,
RNAP in an arrested complex can be subject to degrada-
tion by the ubiquitin/proteosome pathway [20].
Initially we tested effects of siRNA knockdown of several
transcription factors. TFIIS presented the best case for fur-
ther analysis and the TFIIS data is presented herein. Our
evidence indicates that TFIIS knockdown inhibits cell pro-
liferation and induces apoptosis in cancer cells.
Methods
Cell Culture
MCF7 and PL45 cells were grown in DMEM + 10% Fetal
Bovine Serum (FBS) + 1% Penicillin/Streptomycin (Pen/
Strep, Invitrogen). A549 and PC-3 were grown in F-12
(Ham's) Media + 10% Fetal Bovine Serum (FBS) + 1%
Penicillin/Streptomycin (Pen/Strep). MCF10A cells were
grown and plated in MEGM (Clonetics, CC-3150) supple-
mented with Bovine Pituitary Extract (BPE), human
Endothelial Growth Factor (hEGF), hydrocortisone, GA-
1000 and insulin. For assays Pen/Strep was omitted. All
cell lines were obtained from the ATCC.
siRNA Proliferation Assay
siRNAs targeting different regions of human TFIIS are
listed in Table 1. siRNA was generated using the Silencer
siRNA Construction Kit (Ambion #1620) and transfected
into cells using Lipofectamine 2000 (Invitrogen #11668-
019). Cell proliferation assays employ the MTS assay
(Promega, WI). Before transfection, cell lines were seeded
in 96-well plates at a concentration of 2000 cells/well.
Plates were incubated for 24 hrs at 37°C. Lipofectamine
2000 Transfection Reagent (Invitrogen) was mixed with
0.1, 0.5, 1.0, and 5.0 nM Eg5 siRNA (positive control), S-
siRNA negative control (sGAPDH, Ambion), or each of
the TFIIS siRNAs in Opti-MEM I Reduced Serum Medium
(Invitrogen #31985-070). Cells were transfected using the
Opti-MEM containing the transfection reagent and the
siRNA plus their respective growth medium without anti-
biotic. Cells were incubated for 72 hrs at 37°C. Vehicle
containing Lipofectamine 2000 alone was applied to cells
and viable cells considered 100% survival. Assays were
performed in quadruplicate with a minimum of two dif-
ferent experiments. For cell viability, media was replaced
with MEM without Phenol Red, and MTS reagent was
added and allowed to incubate for 2 hrs, at which time the
colorimetric signal was determined, and data analyzed to
obtain the mean and standard error. Graphs were plotted
using Prism (Graphpad Software, Inc., CA). For the prolif-
Table 1: siRNA's Employed in Knockdown Experiments.
Gene Sense Strand Antisense Strand mRNA Target
TFIIS #1 aatgctattcgcaagcagagt aaactctgcttgcgaatagca aaugcuauucgcaagcagagu
TFIIS #2 aacaggggatgactacattgc aagcaatgtagtcatcccctg aacaggggaugacuacauugc
TFIIS #3 aagagatgcggaaaaacttga aatcaagtttttccgcatctc aagagaugcggaaaaacuuga
Sense and antisense template strands shown also contained a cctgtctc T7 promoter primer sequence on the 3' terminal. Once the individual 
template strands had been transcribed, they were hybridized to form the 21-nt double stranded short interfering RNA (siRNA).BMC Cancer 2008, 8:133 http://www.biomedcentral.com/1471-2407/8/133
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eration and caspase assays, a one-way ANOVA was per-
formed for all data generated indicating the overall
significance of the data. However, data which was not sig-
nificant (p > 0.05), was noted in the text of the result sec-
tion.
Knockdown of mRNA by siRNA
Knockdown of mRNA levels was assessed by the Quanti-
gene method as suggested by company protocols (Panom-
ics, Fremont, CA). Controls are listed in materials and
methods above. mRNA levels were directly quantified
from cells grown in 96-well plates. The assay employed 5
nM TFIIS siRNA#2 and expression was normalized to cell
number as determined by the MTS assay. Cells treated
with 5 nM S-siRNA were set at 100% cell proliferation.
C-ELISA
Cells were plated in 96-well plates in quadruplicate. After
a 72-hour exposure to siRNA, media was removed and
3.7% formaldehyde was added as a fixative and allowed
to incubate for 10 minutes. After fixation, cells were
washed with PBS-0.5% Tween (PBS-T) three times for five
minutes each. Cells were then blocked in 5% non-fat milk
+ 1% Bovine Serum Albumin (BSA) in PBS-0.5% Tween
(PBS-T) for one hour at room temperature. Blocking rea-
gent was removed and primary antibody diluted 1:500 in
block buffer was added and left to incubate for one hour
at room temperature. Primary antibody was removed, fol-
lowed by three washes in PBS-T for 1 minute each. Sec-
ondary antibody conjugated to HRP (KPL cat#074-1806)
was added at a dilution of 1:1000 in block buffer and left
to incubate for 1 hour at room temperature. Three PBS-T
washes followed, each for 1 minute. During this time, a
chemiluminescent substrate (Pierce, cat #34095) was pre-
pared and added to the cells and chemiluminescence read
in a Wallac Victor 2 plate reader (Perkin Elmer; Waltham,
MA). Antibodies employed in the assay included c-myc
(Sigma cat#M4439), TFIIS (BD Biosciences cat #611205),
GAPDH (Calbiochem cat#CB1001), and p53 (Sigma
cat#P6874).
Western Analysis
Standard western analysis was performed employing anti-
bodies for TFIIS (BD Biosciences cat #611205) and for α-
tubulin (Santa Cruz Biotechnology cat# sc-58667). 10 nM
siRNA was employed and cells collected at 48 hours to
allow for enough starting material. 2.5 × 106 cells/plate
were plated in 10 cm plates and transfected with siRNA.
After 48 hours, cells were washed in PBS and adherent
cells were collected. RIPA buffer supplemented with 1:100
protease inhibitors was added for 30 minutes and after
centrifugation, protein in the supernatant was collected
and stored at -80°C. Protein was loaded onto a 10% SDS-
PAGE gel and transferred overnight to nitrocellulose at
4°C.
Blocking of the nitrocellulose was performed with 5%
non-fat milk in PBS-0.5% Tween (PBS-T) for one hour at
room temperature. Primary antibody was diluted 1:1000
in 5% non-fat milk PBS-T incubated for one hour at room
temperature. The blot was washed three times in PBS-T for
10 minutes each. Secondary antibody conjugated to HRP
(KPL cat#074-1806) was added at a dilution of 1:5000 in
5% non-fat milk PBS-T and incubated for 45 minutes at
room temperature. The filter was washed three times with
PBS-T washes for 10 minutes each wash and detection was
performed employing an ECL Detection Reagent (Amer-
sham). The filter was exposed to film and images were
scanned and quantified by Imagequant (BioRad).
Apoptosis
Apoptosis was tested by an enzymatic and nonenzymatic
assay. Each assay was performed in quadruplicate with a
minimum of two independent experiments. For the enzy-
matic assay, cells were treated as indicated for the MTS
proliferation assay with MTS being substituted by the Cas-
pase Glo-3/7 Assay reagent (Promega cat #G8091) and
plates read as instructed by the manufacturer. Values for
caspase activity were divided by the amount of viable cells
as represented by MTS values and normalized to similar
data from vehicle treated cells. The data was analyzed to
obtain the mean and standard error, and graphs were plot-
ted using Prism (Graphpad Software, Inc., CA).
For the nonenzymatic assay we employed the Cell Death
Detection ELISAPLUS  Assay (Roche Cat. No.
11774425001), which determines the level of cytoplas-
mic mono- and oligonucleosomes induced by apoptosis.
Cells were treated with 5 nM TFIIS siRNA #2, or 5 nM S-
siRNA in 6-well plates, incubated at 72°C for 72 hours,
and the assay completed as recommended by the manu-
facturer. Enrichment of mono- and oligonucleosomes was
determined by dividing TFIIS siRNA values by those of
cells treated with 5 nM S-siRNA. The data was analyzed to
obtain the mean and standard error, and graphs were plot-
ted using Prism (Graphpad Software, Inc., CA)
Gene Arrays
I) Experimental Design
A total of two experiments were completed with 4 chips
each, so that the microarray replicates were performed in
duplicate for a total of 8 chips. Details of the experimental
design can be found in Table 2.
II) Generation of Probes
Arrays were preformed in duplicate as previously
described [21]. Oligonucleotide glass array containing a
total of 16,659 seventy-mer oligonucleotides chosen from
750 bases of the 3' end of each ORF (Operon Inc. Valen-
cia, CA) spanning approximately 50% of the human
genome and produced spotting oligonucleotides on poly-BMC Cancer 2008, 8:133 http://www.biomedcentral.com/1471-2407/8/133
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L-lysine coated glass slides by Gene Machines robotics
(Omnigrid, San Carlos, CA). Total RNA was isolated from
TFIIS#2 and S-siRNA treated MCF7 and MCF10A cell lines
using the Trizol reagent (Invitrogen). The precise probe
and control employed for each chip is provided in addi-
tional file 1.
Labeled cDNA was produced as previously described [22].
Briefly, 5 μg of total RNA was dissolved in 12 μl of DEPC
water and incubated at 70°C for 5 minutes along with 1
μl of aminoallyl-oligo dT (5' amino-modified) primer and
chilled for 3 minutes. Then, 1.5 μl AffinityScript reverse
transcriptase (Stratagene, La Jolla, CA), 2 μl of 10× first
strand buffer supplied with the reverse transcriptase, 1.5
μl dNTP mix (10 mM dATP, dGTP, and dCTP, 6 mM
dTTP, 4 mM amino-allyl dUTP), and 2 μl of 0.1 M DTT
were added and incubated for 90 minutes at 44°C. After
incubation, the volume of the reaction mixture was
brought to 60 μl with 40 μl DEPC water. 300 μl of Binding
buffer PB was added to the coupled cDNA, and the mix-
ture applied to a MinElute column (Qiagen, Valencia,
CA), centrifuged for 1 minute at maximum speed and
washed twice with 400 μl of buffer PE. The center of the
membrane was incubated at room temperature for 1 min
with 10 μl elution buffer for 1 min and centrifuged for 1
min at max speed to elute the cDNA probe. Finally, 5 μl of
0.4 M NaHCO3 coupling buffer and 10 pmol of either Cy3
or Cy5 dye dissolved in 5 μl DMSO was added to the con-
trol (MCF7 or MCF10A cells treated with S-siRNA) or
experimental cDNAs (MCF7 and MCF10A treated with
TFIIS siRNA). The reaction was incubated at room temper-
ature in the dark for 90 minutes. The volume was then
brought to 60 μl by the addition of 50 μl DEPC water and
cDNA was purified by MinElute column as described
above. Finally, the Cy3 and Cy5 labeled cDNAs were
mixed.
III) Hybridization
Samples were heated at 100°C for 2 minutes and 25 μl
hybridization buffer (Slide Hyb#1 Catalog #8861,
Applied Biosystems, Foster City, CA) was added to the
labeled probes. Then, 42 μl of probe was added to the
arrays covered with a MAUI®  Mixer FL hybridization
chamber (Biomicrosystems, Salt Lake City, UT). Slides
were placed into a 4-bay MAUI® Hybridization System
Instrument overnight (14–16 hours) at 42°C, then
washed for 5 minutes each in 1× SSC and 0.1× SSC and
spin-dried at 500 ×g.
IV) Data filtration, Normalization, and Analysis
Microarray slides were scanned in Cy3 (532 nm) and Cy5
(635 nm) channels using Axon GenePix 4000B scanner
(Axon Instruments, Inc., Foster City, CA) with a 10-
micron resolution and exported as TIFF files to GenePix
Pro 3.0 software for image analysis. The raw images were
collected at 16-bit/pixel resolutions with 0 to 65,535
count dynamic range. Background values were not sub-
tracted. The resulting GenePix data was imported into
ArrayTrack Software (Food and Drug Administration,
National Center for Toxicological Research) [23]. The data
was normalized using the software's LOWESS and linear
normalization methods. A t-test was performed on the
scrambled control vs. the TFIIS siRNA treated groups for
each cell line to get the list of differentially expressed
genes (Test 1 = MCF7 scrambled control vs. MCF7 treated;
Test 2: MCF10A scrambled control vs. MCF10A siRNA
treated). A Bonferroni adjusted p-value was too stringent
and yielded no significant genes. A p-value of 0.05 was
used while adding a more stringent fold-change criteria
(1.3). Using both a p-value and fold change cut-offs are in
accordance with the results of reproducibility found by
the Microarray Quality Control Consortium (Nature Bio-
technology, September 2006 Vol. 24 No. 9 issue). The lists
were then imported into the Ingenuity database for path-
way analysis (Ingenuity, Redwood City, CA).
Results
Differential effects of TFIIS knockdown on MCF7 and 
MCF10A cell lines
We determined effects of TFIIS siRNA on the proliferation
of both cancerous MCF7 and non-cancerous MCF10A
breast cell lines (Figure 1). For validation purposes three
different siRNAs targeting different regions of human
TFIIS lacking homology to other human genomic
Table 2: Gene Array: Experimental Design
Chip number Cy 3 label Cy 5 label
1 Reference: MCF7 RNA with scrambled control sequence MCF10A w/scrambled control sequence
2 Reference: MCF7 RNA with scrambled control sequence MCF10A w/TFIIS siRNA sequence
3 Reference: MCF7 RNA with scrambled control sequence MCF7 w/scrambled control sequence
4 Reference: MCF7 RNA with scrambled control sequence MCF7 w/TFIIS siRNA sequence
5 Reference: MCF7 RNA with scrambled control sequence MCF10A w/scrambled control sequence
6 Reference: MCF7 RNA with scrambled control sequence MCF10A w/TFIIS siRNA sequence
7 Reference: MCF7 RNA with scrambled control sequence MCF7 w/scrambled control sequence
8 Reference: MCF7 RNA with scrambled control sequence MCF7 w/TFIIS siRNA sequenceBMC Cancer 2008, 8:133 http://www.biomedcentral.com/1471-2407/8/133
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sequences were employed (Table 1). A scrambled GAPDH
siRNA (S-siRNA, Ambion, cat #4605) was employed as a
negative control. Eg5 siRNA was employed as positive
control. Eg5 is required for the formation of the bipolar
spindle and chromosome separation [24,25] and has
been determined to be an effective control for siRNA
experiments [25]. Eg5 is also a cancer target [26] so that it
provides for an effective comparison with transcription
factor siRNAs. Effects of Eg5 knockdown are known to
vary depending on cell line, and can either inhibit cell
division preventing proliferation, or induce apoptosis
[27].
We also determined if reduced proliferation by TFIIS
siRNA occurs concomitantly with activation of caspases 3
and 7 by employing an assay that detects the sum of cas-
pases 3 and 7 activities. MCF7 cells lack functional caspase
3 so that the caspase-3/7 activity assay in those cells repre-
sents caspase 7 activity alone [28]. Detection of caspase-3/
7 activity was employed since caspase 7 is a critical medi-
ator of mitochondrial events of apoptosis [29].
In MCF7 cells, all three TFIIS siRNAs induced a dramatic
concentration-dependent reduction in cell proliferation
and an increase in caspase-3/7 activity (Figure 1). A one-
way ANOVA confirms that all differences in cell prolifera-
Effects of TFIIS siRNA on Cell Proliferation Figure 1
Effects of TFIIS siRNA on Cell Proliferation. MCF7 and MCF10A cell lines were subjected to siRNA directed at TFIIS as 
listed in Table 1, scrambled siRNA (S-siRNA) or Eg5 and MTS values determined 72 hours after transfection. Cell proliferation 
represents the fraction of viable cells compared to cells transfected with vehicle alone (1 = 100% viable cells when treated with 
vehicle alone). Standard error of the mean is indicated as bars in the figure. Caspase-3/7 activity is also depicted and normalized 
to cell number represented by MTS values. Total activity was then normalized to activity in cells treated with vehicle alone.BMC Cancer 2008, 8:133 http://www.biomedcentral.com/1471-2407/8/133
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tion and caspase-3/7 activity between 5 nM S-siRNA and
5 nM TFIIS siRNAs were significant (p < 0.001). However,
there was no significant difference in caspase-3/7 activity
between S-siRNA and Eg5 treated cells. Compared to
MCF7, TFIIS siRNA treated MCF10A cells displayed signif-
icantly less growth inhibition. The overall higher values of
caspases 3/7 activity in the MCF10A cells are to be
expected because of the absence of caspase 3 activity in
MCF7 cells [28]. In both MCF7 and MCF10A, the negative
control S-siRNA had relatively limited off-target effects on
cell proliferation and the positive Eg5 siRNA control was
effective in reducing proliferation as expected. However,
Eg5 siRNA inhibition of proliferation was greater in
MCF10A than in MCF7 even at relatively lower concentra-
tions of siRNA. This is consistent with variable effects of
Eg5 knockdown on different cell lines [27].
The ratio of proliferation of MCF10A to MCF7 when
treated with TFIIS siRNA normalized to S-siRNA control
proved to be significant and positive (Figure 2A). At the
highest concentration of TFIIS siRNA#3 (5 nM), a 6-fold
anti-proliferative ratio existed between non-cancer and
cancer cells (4.9-fold for TFIIS siRNA#2). The anti-prolif-
erative effects of TFIIS siRNA, on MCF7 cells was also asso-
ciated with cell death as determined by a trypan blue
exclusion cell viability assay (Figure 2B). Initially, 2,000
cells were plated per well. Seventy-two hours after treat-
ment with 5 nM TFIIS siRNA#2, only 140 (± 26) MCF7
cells survived whereas treatment with vehicle or S-siRNA
resulted in 10,425 (± 3,012) or 8,600 (± 1,998) viable
cells respectively. Essentially, MCF7 cannot survive treat-
ment with TFIIS siRNA.
TFIIS siRNA reduces proliferation of cancer cells of 
different origin
It was not initially clear if TFIIS siRNA would have a can-
cer type specific effect, so that we also tested lung, A549
and pancreas PL45 cell lines in our proliferation and cas-
pase 3/7 assays (Figure 3). Both A549 and PL45 cell lines
proved susceptible to TFIIS siRNA in a concentration-
dependent manner with A549 displaying a greater suscep-
tibility than PL45 (Figure 3). Inhibition of proliferation as
a result of the positive control Eg5 siRNA indicated effec-
tive transformation and all three TFIIS siRNAs provided
similar inhibition profiles in accord with specificity of tar-
geting. However, S-siRNA itself inhibited proliferation in
A549 cells to a greater extent than for MCF7, MCF10A or
PL45, indicating that some cell lines may be more suscep-
tible to non-specific effects of siRNA than others.
When comparing TFIIS siRNA proliferation profiles of
MCF7, A549, and PL45 to the noncancerous cell line
MCF10A, MCF7 displayed the greatest differential. A549
cells presented a significant increased level of inhibition
of proliferation of A549 compared to MCF10A only at low
TFIIS siRNA is specific for cancer cells and causes cell death Figure 2
TFIIS siRNA is specific for cancer cells and causes cell death. (A) MCF10A (Black) and MCF7 (White) cell lines were 
subjected to siRNA directed at TFIIS employing siRNA#3 and proliferation determined 72 hours after treatment. siRNA con-
centrations and the fraction of cell proliferation normalized to S-siRNA treated cells are indicated (1 = 100% viable cells when 
treated with S-siRNA). The ratio of cell proliferation between MCF10A and MCF7 cells is shown above the bars. (B) The bar 
graph represents the number of trypan blue excluded cells. Plated, represents the number of cells initially seeded. Media repre-
sents the number of cells when employing unmodified media. Also listed is the number of viable cells after treatment of MCF7 
with lipid transfer vehicle identified as "Vehicle" TFIIS siRNA, S-siRNA or Eg5 siRNA. Data points represent mean and standard 
error. Proliferation was determined 72 hours after siRNA treatment.BMC Cancer 2008, 8:133 http://www.biomedcentral.com/1471-2407/8/133
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siRNA concentration, and there was no significant differ-
ence between PL45 and MCF10A cells.
It is also important to note that 5 nM TFIIS siRNA induced
caspase-3/7 activation for all cell lines tested. The only
exception was for PL45 cells, in that a one-way ANOVA
indicates no significant caspase 3/7 activity at lower TFIIS
siRNA concentrations and a minimal signal relative to S-
siRNA at 5 nM TFIIS siRNAs #1 and #3 (p < 0.001 and p <
0.05 respectively). Eg5 siRNA induced dramatic caspase 3/
7 activity in MCF10A and PL45 and minimal increases in
MCF7 and A549 cell lines, in accord with differential
effects of Eg5 inhibition on diverse cell lines [27].
To further validate the enzymatic caspase 3/7 apoptosis
data, we employed a non-enzymatic assay to detect cyto-
plasmic mono- and oligonucleosomes, which are conse-
quences of apoptosis (Figure 4). In the assay MCF7 cells
treated with 5 nM TFIIS siRNA #2 displayed a robust
increase in apoptotic activity while A549 and MCF10A
cells showed a modest two-fold increase compared to S-
siRNA. Apoptosis was not statistically significant in PL45
cells. This is in good accord with the caspase data, where
TFIIS siRNA induced pronounced dose-dependent cas-
pase activity in MCF7 cells, yet barely any activity in PL45
cells. It also correlates well with the high sensitivity and
effective elimination of MCF7 cells as a result of TFIIS
siRNA.
Effects of TFIIS siRNA on proliferation of lung A549 and pancreatic PL45 cells Figure 3
Effects of TFIIS siRNA on proliferation of lung A549 and pancreatic PL45 cells. A549 and PL45 cell lines were sub-
jected to siRNA directed at TFIIS #1–3, Scrambled siRNA (S-siRNA), or Eg5. Cell proliferation represents the fraction of viable 
cells compared to cells transfected with vehicle alone (1 = 100% viable cells). Caspase-3/7 activity is also depicted and normal-
ized to cell number represented by MTS values. Total activity was then normalized to activity in cells treated with vehicle 
alone. TFIIS siRNA #2 nearly perfectly overlays TFIIS siRNA #1 in MCF7 cells and is therefore mostly not visible. Data points 
represent mean and standard error. The assay was performed 72 hours after initial siRNA transfection.BMC Cancer 2008, 8:133 http://www.biomedcentral.com/1471-2407/8/133
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TFIIS siRNA effects are due to a reduction in TFIIS mRNA 
and protein levels
We determined TFIIS mRNA levels employing TFIIS
siRNA#2 and the Quantigene method as suggested by the
manufacturer (Panomics [30]). TFIIS mRNA levels were
31.0 ± 1.6% for MCF7 and 45.4 ± 5.0% for MCF10A when
compared to the 100% levels set for S-siRNA treated cells.
To determine TFIIS protein levels in 5 nM TFIIS siRNA
treated MCF7 and MCF10A cells, we employed a C-ELISA
assay and GAPDH antibodies as control. GAPDH proved
to be a valid control as GAPDH and cell proliferation were
linearly correlated (supplemental data). TFIIS protein lev-
els in MCF7 cells were 0.43 ± 0.1 and 0.28 ± 0.07 for
MCF10A when compared to TFIIS levels set at 1 for TFIIS
siRNA treated cells. The mRNA data might suggest that
MCF10A did not respond as dramatically to TFIIS siRNA
because it maintained a higher level of TFIIS mRNA. How-
ever, relative protein levels for TFIIS were lower in
MCF10A than in MCF7.
Although the high degree of MCF7 cell death caused by
TFIIS siRNA limited the amount of protein attainable,
starting from large quantities of cells, we were able to per-
form a western analysis of TFIIS employing tubulin for
normalization (Figure 5). The western indicated a 53%
reduction in the amount TFIIS protein in TFIIS siRNA#2
treated cells. In S-siRNA-treated cells, TFIIS protein was
90% of control indicating that off-target effects of S-siRNA
on TFIIS are minimal. The western data roughly conforms
to the level of reduction of TFIIS in the C-ELISA assay.
Results from a "recovery" assay indicate that the reduction
of TFIIS mRNA was specifically responsible for MCF7 cell
death (Figure 6). In the assay, a human TFIIS expression
plasmid (TFIIS in pCMV-XL5; OriGene, Rockville, MD)
was co-transfected with TFIIS siRNA to increase TFIIS
mRNA. If inhibition of cell proliferation was a result of
TFIIS mRNA knockdown, then additional TFIIS mRNA
from the expression plasmid should recover cell prolifera-
tion. Indeed, the addition of the TFIIS expression plasmid
resulted in a dramatic rescue of cell proliferation, indicat-
ing that inhibition of proliferation was a specific result of
TFIIS knockdown.
TFIIS knockdown activates P53 and c-myc in MCF7 cells
We employed a C-ELISA assay to assess relative amounts
of TFIIS, c-myc and p53 in TFIIS siRNA treated MCF7 and
MCF10A cells (Figure 7). GAPDH protein was employed
as a baseline and relative levels of TFIIS, c-myc and p53
were determined. TFIIS siRNA reduced relative levels of
TFIIS in both cancerous MCF7 and non-cancerous
MCF10A cells in a dose dependent manner (Figure 7).
However, MCF7 displayed a dose dependent increase of
both c-myc and p53 of greater than 2.5-fold at 5 nM TFIIS
siRNA. This was not the case for MCF10A cells, where
Western analysis indicates reduced TFIIS protein after TFIIS  siRNA treatment Figure 5
Western analysis indicates reduced TFIIS protein 
after TFIIS siRNA treatment. For the Western analysis, 
MCF7 cells were treated with vehicle, S-siRNA or TFIIS 
siRNA#2 as indicated. TFIIS and alpha-tubulin monoclonal 
antibodies were employed to detect their respective pro-
teins. The ratio of TFIIS to alpha-tubulin as determined by 
imagequant (BioRad) is depicted by the bar-graph and listed 
as well above the columns. Cells were collected 48 hours 
after initial siRNA treatment.
Enrichment of Mono- and Oligonucleosomes after introduc- tion of TFIIS siRNA Figure 4
Enrichment of Mono- and Oligonucleosomes after 
introduction of TFIIS siRNA. MCF7, PL45, A549 and 
MCF10A cells were treated with 5 nM TFIIS #2 siRNA and S-
siRNA. Mono- and oligonucleosome values were normalized 
to cells treated with S-siRNA, so that a value of one repre-
sents a lack of apoptosis. Assays were performed for 72 
hours.BMC Cancer 2008, 8:133 http://www.biomedcentral.com/1471-2407/8/133
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both c-myc and p53 displayed a modest decrease in pro-
tein levels.
Gene Array analysis of TFIIS siRNA in MCF7 and MCF10A
To gain further insight on effects of TFIIS siRNA on MCF7
and MCF10A cells, gene array studies were performed. The
cDNA probes were from either 5 nM TFIIS siRNA treated
MCF7 or MCF10A cells, and control cDNAs were from S-
siRNA treated MCF7 or MCF10A cells. The experimental
design allows for determining altered expression in MCF7
and MCF10A cells compared to expression in 5 nM S-
siRNA treated cells (for experimental design, see table 2).
Of the 16,659 70-mers, 58 genes (focus genes) displayed
TFIIS knockdown specific expression changes unique to
MCF10A and 49 unique focus genes were disclosed for
MCF7, with one focus gene in common [see additional
file 1].
Pathway analysis of the significant gene lists from above
were imported into Ingenuity® software (Figures 8, 9, 10,
[31]). Pathways consist of a network of genes or proteins
that directly or indirectly affect each other. Focus genes
from the array were mapped to their corresponding gene
in the Ingenuity Pathways. Ingenuity Pathway scores are
derived from a p-value indicating the likelihood of the
focus genes being found together due to random chance.
A score of 2 indicates that there is a 1 in 100 chance that
the focus genes are together in a network due to random
chance. The top MCF7 pathways had scores of 40 and 15
and the top MCF10A pathways had scores of 37 and 25.
The remaining pathways had scores of 2 and 3, and were
not employed in our analysis to assure for highly signifi-
cant data. For illustration purposes, pathways 1 of MCF7
(figure 8) and 1 and 2 of MCF10A are presented (Figures
9 and 10 respectively) with genes of the highly significant
pathways listed in Additional file 1.
Some major "hubs" affected by TFIIS siRNA as disclosed
in the pathway analysis include c-myc, p53, and estradiol
for both MCF7 and MCF10A and the mitogen-activated
protein kinase (MAPK) signaling pathway in MCF10A
alone.
Discussion
Use of siRNA for studying effects of protein knockdown for 
cancer therapy
siRNA was employed to study the effects of TFIIS knock-
down on cancer cells. Several lines of evidence indicate
that siRNA methodologies employed for the analysis of
TFIIS were valid. These include the effectiveness of the
positive Eg5 control, the relatively limited effect of S-
siRNA and the similar effects of three different TFIIS siR-
NAs directed at different regions of the TFIIS mRNA.
Regarding Eg5, its inhibition of proliferation reached
maximal effects at the low concentration of 0.5 nM siRNA
in all cell lines (figures 1 and 3) so that transfection effi-
ciencies in the different cell lines are comparable. TFIIS
siRNA also induced a reduction in TFIIS mRNA and pro-
tein. Finally, recovery of proliferation reduced by TFIIS
siRNA is attained by the addition of a TFIIS expression
vector.
At the 5 nM TFIIS siRNA concentration, the reduction of
mRNA and protein was not complete, nor was it expected
to be. Even higher siRNA concentrations do not always
allow for absolute protein or mRNA reduction. For exam-
ple, siRNA reduction of Akt-1 was reported to be 51 and
73% effective for 20 and 80 nM siRNA, respectively [32].
In general, siRNA concentrations employed for knock-
down by others are higher than those employed in the
current study (20–100 nM) [32-34]. In our case, it was not
necessary, nor possible to increase siRNA levels beyond 5
nM as we had nearly complete elimination of the MCF7
cells and significant reduction in proliferation of other
cancer types. Furthermore, increasing siRNA levels is
accompanied by increased nonspecific effects known as
"off target effects" [32,35-37].
TFIIS Recovery Assay Figure 6
TFIIS Recovery Assay. The TFIIS mammalian expression 
vector pCMV6-XL5 was purchased from Origene. MCF7 
cells were co-transfected with 89, 107 and 125 ng of the 
TFIIS:pCMV6-XL5 plasmid and 0.1, 0.5, 1.0, 5.0 nM TFIIS 
siRNA. In addition, 178 ng of a control pCMV6-XL5 plasmid 
with no TFIIS insert was transfected with 0.1, 0.5, 1.0 and 5.0 
nM TFIIS siRNA. For control, 100% proliferation was set as 
proliferation of cells treated with vehicle + plasmid alone 
(without siRNA) at the relevant concentrations. Data points 
represent mean and standard error. Cell proliferation was 
determined 72 hours after initial transfection of siRNA and 
expression vector.BMC Cancer 2008, 8:133 http://www.biomedcentral.com/1471-2407/8/133
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Pathways affected by TFIIS knockdown
c-myc and p53 were major "hubs" in the TFIIS knock-
down pathway for both MCF7 and MCF10A (pathway 1
of MCF7, figure 8 and pathway 1 of MCF10A, figure 9), in
accord with the C-ELISA data of altered protein levels of
p53 and c-myc. c-myc itself was not represented on the
gene array and the p-value for p53 did not match our sta-
tistical criteria. However, increased c-myc expression in
MCF7 and decreased c-myc expression in MCF10A fits
well with the expression pattern of focus genes on the
array. For example, in MCF7 arrays, downregulation of
BRD2 and MYCN is in accord with c-myc repression of
both genes [38,39]. Regarding MCF10A, the modest
decrease in c-myc observed by the C-ELISA assay concurs
with a decrease in expression of HGMN2 and C6ORF108
both of which are induced by c-myc [38,40]. Decreased c-
myc in MCF10A also agrees with an increase in PERP as c-
myc protein represses expression of PERP [41]. IL15
induces c-myc expression and the MCF10A array results
indicate a decrease in IL15 expression in full agreement
with decreased myc protein [42,43]. As such the gene
array data correlates well with the C-ELISA data indicating
increased c-myc in MCF7 and decreased levels in
MCF10A.
Another hub of genes affected by TFIIS knockdown com-
mon to both MCF7 and MCF10A was beta-estradiol (Fig-
ures 7A and 7C). TFIIS knockdown appears to mimic the
effects estrogen has on gene expression. More specifically,
estradiol induces expression of PRKCZ and CFHR4
[44,45] and both increase on our MCF7 TFIIS knockdown
array. Estradiol also induces expression of c-myc [46] and
p53 [47] concurring with increased protein levels of both
in MCF7 cells. Regarding MCF10A, a decrease in
CYP51A1, EIF2S1 [48], and ACADVL [48] are all in accord
with effects of estrogen on gene expression. However,
estradiol also increases c-myc and p53 expression and in
contrast MCF10A had moderately reduced levels of both
proteins. In addition, within the estradiol expression
pathways of MCF7 and MCF10A, different focus genes
were affected [see Additional file 1]. It appears that TFIIS
knockdown affects some similar pathways including c-
myc/p53 and estradiol in both cell lines, though the effect
on the particular expression of genes in the pathways dif-
fers and may contribute to the dissimilar consequences of
TFIIS knockdown.
Another difference between MCF7 and MCF10A was the
reduced expression of some components in the mitogen-
activated protein kinase (MAPK) signaling pathway in
MCF10A alone, as a result of TFIIS knockdown. For exam-
ple, EDG4, a member of the G-coupled protein receptor
family was downregulated. GNB1 a G-protein Ras signal-
ing transducer and Map2K2 (MEK2), which phsophor-
ylates MapK, displayed reduced-expression as well. PLD2
(phsopholipase D2) expression was increased in the
TFIIS-knockdown MCF10A array. PLD2 is known to be
involved in EGF receptor internalization and degradation
Relative protein levels of TFIIS, c-myc and p53 were determined in MCF7 and MCF10A cells Figure 7
Relative protein levels of TFIIS, c-myc and p53 were determined in MCF7 and MCF10A cells. Protein values were 
determined for TFIIS siRNA #2 (Table 1) relative to GAPDH protein levels (TFIIS, c-myc or P53/GAPDH) and normalized with 
protein levels similarly determined from control S-siRNA treated cells. siRNA concentrations from 0.1 to 5.0 nM and standard 
error are indicated for each siRNA concentration. Data points represent mean and standard error and the assay performed 72 
hours after initial siRNA transfection.BMC Cancer 2008, 8:133 http://www.biomedcentral.com/1471-2407/8/133
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[49]. As such it appears that TFIIS activates expression in a
manner consistent with estradiol pathways in both
MCF10A and MCF7 and reduces signal transduction path-
ways in MCF10A cells.
TFIIS knockdown and the induction of cancer cell death
TFIIS knockdown is likely to set into effect a cascade,
which modifies the level of expression of specific genes.
Possible routes to invoke cancer cell death involve repres-
sion of oncogenes or activation of tumor suppressors. For
example, it was previously shown that c-myc and c-fos
oncogenes contain poly T stretches that pause or arrest
transcription in vitro [14] and that those sites are TFIIS
responsive [15,50-52]. As such we originally thought that
TFIIS knockdown would decrease c-myc expression. Our
observed increase in c-myc levels in MCF7 cells suggests
that in vitro assays do not necessarily mirror in vivo effects.
Other transcription elongation factors such as ELL,
Elongin and TFIIF may suppress arresting at intrinsic sites
in vivo [53] so that TFIIS may not necessarily play the key
and prominent role of regulating c-myc elongation. Fur-
thermore, although loss of c-myc activity is associated
with tumor cell death [54], overexpression of c-myc can
also be proapoptotic [55-58].
Another possibility is that TFIIS knockdown could alter
transcription patterns and induce expression of a tumor
suppressor gene. In this regard, inhibition of RNA
Major pathways affected by TFIIS knockdown in MCF7 Figure 8
Major pathways affected by TFIIS knockdown in MCF7. Network analysis employed Ingenuity® Systems software [31]. 
The software manufacturer maintains a copyright on the image networks. The Ingenuity networks display in color focus genes 
that are upregulated (green) and downregulated (red) by other proteins. The affect can be direct (solid lines) or indirect (bro-
ken lines). Triangle's represent kinases, diamonds enzymes, ovals Transcription regulators, rectangles G–Protein Coupled 
receptors and circles, other. The pathway represents MCF7 pathway 1. A list of focus genes for each pathway is provided in 
Additional file 1.BMC Cancer 2008, 8:133 http://www.biomedcentral.com/1471-2407/8/133
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Polymerase II has been implicated as resulting in activa-
tion of the p53 tumor suppressor [59,60], which is known
to induce tumor regression [61]. Although TFIIS knock-
down is not synonymous with RNAP inhibition, p53
could play a role in MCF7 cell death. Our data indicates
that TFIIS knockdown does result in increased levels of
p53 in MCF7 but not in MCF10A.
An additional pathway affected by TFIIS siRNA in both
MCF7 and MCF10A was the β-estradiol hub, where TFIIS
knockdown appears to mimic the activation of genes by
estradiol. Although estrogen may be present in culture
media, it was unlikely that the estrogenic pathway dis-
closed by the Ingenuity pathway software resulted from
estrogen in the media as MCF10A does not express the
estrogen receptor. In addition, identical conditions of cell
growth (including any estrogen present in media) were
employed for both control S-siRNA and TFIIS-siRNA
treated cells. As such all pathways including the estrogenic
pathway disclosed by the Ingenuity software can only be
attributed to effects of TFIIS siRNA.
In addition to the increased p53 and c-myc in MCF7 cells,
the induction of an estradiol "transcriptional overdose",
may have ultimately contributed to MCF7 cell death.
When breast cancer cells, including MCF7, are deprived of
estrogen, they can develop estrogen hypersensitivity so
that the addition of estrogen induces apoptosis [62,63].
Recent clinical considerations in treating estrogen refrac-
tory breast cancer includes use of estrogen on the estrogen
hyper-sensitized cancer cells in post-menopausal women
[62]. In MCF10A cells, the expression snapshot differs in
some ways from MCF7. The activation of different focus
genes in the estrogenic pathway, along with the moderate
MCF10A Pathway 1 affected by TFIIS knockdown Figure 9
MCF10A Pathway 1 affected by TFIIS knockdown. The figure represents MCF10A pathways 1 derived from the Ingenu-
ity® Systems program, which maintains a copyright on the image networks. Labeling of the network is similar to that of figure 8.BMC Cancer 2008, 8:133 http://www.biomedcentral.com/1471-2407/8/133
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reduction of c-myc and p53, and reduced expression of
components of the MapK signal transduction pathway are
all likely to have been a determinant in its greater resist-
ance to TFIIS siRNA.
TFIIS is primarily an elongation factor and TFIIS knock-
down should primarily affect the efficiency of actively
transcribed genes rather than activating new pathways.
The β-estradiol hub is likely to be one of the active path-
ways in MCF7 and MCF10A cell lines of breast origin. This
may in part explain why only one common focus gene
was disclosed on the gene array. Only genes actively
expressed in both MCF7 and MCF10A that contain TFIIS
responsive arrest sites would be disclosed on the array. It
is possible that there were other common focus genes in
common between MCF7 and MCF10A that were masked
by off target affects of the S-siRNA control. For example,
siRNA itself causes some degree of Caspase 3/7 activation
so that genes in the apoptotic pathway may not be
observed.
TFIIS as a possible target for therapeutics for breast and 
other Cancers
Aberrant gene expression is a hallmark of cancer cells. We
propose that a further insult to the aberrant expression in
cancer cells could cause cancer cell death with limited
effects on normal cells, which maintain healthy transcrip-
tion. The goal is to alter rather than inhibit transcription.
Indeed, extended inhibition of RNAP is likely to be toxic
MCF10A Pathway 2 affected by TFIIS knockdown Figure 10
MCF10A Pathway 2 affected by TFIIS knockdown. The figure represents MCF10A pathways 2 derived from the Ingenu-
ity® Systems program, which maintains a copyright on the image networks. Labeling of the network is similar to that of figure 8.BMC Cancer 2008, 8:133 http://www.biomedcentral.com/1471-2407/8/133
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as alpha-amanitin, an RNAP inhibitor from the mush-
room genus Amanita, is fatal if ingested [64].
For a cancer target to be justified, its inhibition must not
only eradicate cancer cells, but should also be tolerated on
the cellular and physiological levels. Data from clinical tri-
als of HDAC inhibitors and Flavopiridol, both of which
effect transcription mechanisms, indicates a degree of
physiological tolerance to transcription-modifying agents
[13,65]. In vivo knockout experiments also confirm that
TFIIS depletion may be tolerated on the cellular and phys-
iological levels. In yeast TFIIS knockout strains are viable
[66,67]. In TFIIS knockout mice, TFIIS had a critical role
in definitive haematopoiesis and embryos did not come
to term because they were anemic [68]. However, TFIIS
knockout did not prevent cell growth, differentiation or
development and embryos showed similar overall organ
development until E13.5 when the lack of terminal differ-
entiation and red ghosts took its toll [68].
The inhibition of haematopoiesis in mice by TFIIS knock-
out should not deter further study of TFIIS as a cancer tar-
get. First, even if TFIIS knockout inhibits haematopoiesis,
red blood ghosts already exist in an adult. In addition, cur-
rent chemotherapy protocols can employ agents that
damage haematopoeisis (along with other cells that rap-
idly divide), and can be treated with transfusions in severe
cases. Second, in knockout mice, the lack of TFIIS is com-
plete and exists since inception. In our study, the reduc-
tion of TFIIS was not complete, yet was sufficient to
induce dramatic cell death in the MCF7 cell line. Finally,
RNAP arrests at specific DNA sequences whereupon TFIIS
exerts its role in reinitiating transcription. There exists
some degree of sequence difference between mouse and
human DNA so that a similar inhibition of haematopoie-
sis in humans needs to be confirmed.
In the case of TFIIS, the non-cancerous MCF10A cell line
was dramatically less affected than MCF7 cells. MCF10A
cells were employed as a control for cancer cells because
they are not tumorigenic and have been used as a "nor-
mal" control by others [1]. However, it is unlikely that
MCF10A truly represents a "normal" cell. MCF10A does
display genomic alterations, modified expression of some
genes such as ERK1, and does grow in 3-D semi-solid
medium [69,70]. This may explain why there is no differ-
ence in proliferation between the PL45 cells and the
MCF10A cells and minimal (only at low siRNA concentra-
tions) differences between A549 and MCF10A. It is likely
that transcription in most immortalized cells is aberrant
so that targeting the transcription apparatus in immortal-
ized cells may also affect cell viability.
Conclusion
Our data suggests that further studies assessing transcrip-
tion factors and specifically TFIIS for cancer therapy are
called for. At the core of our reasoning are the minimal
effects of S-siRNA on cancer cell proliferation and the
effective inhibition of proliferation by siRNA directed at
TFIIS. This is in full accord with effects of the well-studied
anticancer agent flavopiridol, which induces apoptosis
and has recently been shown to act by inhibition of tran-
scription elongation [71,72]. However, we also draw
attention to an inherent challenge in cell culture analysis
of transcription factor knockdown. Cell lines are unlikely
to present "normal" transcription so that targeting tran-
scription in culture may not allow for a complete picture
of the effectiveness of targeting the transcription machin-
ery. However, siRNA and cell culture may provide for an
initial indication of transcription factors such as TFIIS that
should be targeted for further investigation.
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